Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
53.62
-0.39 (-0.72%)
Nov 19, 2024, 4:00 PM EST - Market closed
Keros Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Keros Therapeutics stock have an average target of 91.43, with a low estimate of 60 and a high estimate of 105. The average target predicts an increase of 70.51% from the current stock price of 53.62.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for KROS stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +86.50% | Nov 7, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Oct 24, 2024 |
| Scotiabank | Scotiabank | Buy Initiates $77 | Buy | Initiates | $77 | +43.60% | Oct 16, 2024 |
| Guggenheim | Guggenheim | Strong Buy Initiates $96 | Strong Buy | Initiates | $96 | +79.04% | Sep 23, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $81 → $76 | Strong Buy | Maintains | $81 → $76 | +41.74% | Sep 12, 2024 |
Financial Forecast
Revenue This Year
2.01M
from 151.00K
Increased by 1,232.45%
Revenue Next Year
4.56M
from 2.01M
Increased by 126.39%
EPS This Year
-5.27
from -5.20
EPS Next Year
-5.77
from -5.27
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 31.6M | 65.6M | 138.6M | ||
| Avg | 2.0M | 4.6M | 28.3M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 20,844.4% | 3,162.9% | 2,941.7% | ||
| Avg | 1,232.5% | 126.4% | 520.6% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.97 | -4.37 | -2.29 | ||
| Avg | -5.27 | -5.77 | -5.62 | ||
| Low | -5.42 | -6.42 | -7.66 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.